High levels of T-cells from common cold coronaviruses can provide protection against COVID-19, an Imperial College London study published on January 10 found, which could inform approaches for second-generation vaccines.

The Omicron variant of the virus that causes COVID-19 likely acquired at least one of its mutations by picking up a snippet of genetic material from another virus – possibly one that causes the common cold – present in the same infected cells, according to researchers.

People who received the one-dose Johnson & Johnson Covid-19 vaccine may need a booster shot to fend off some of the worrisome coronavirus variants now spreading worldwide, a study suggests.

While a failed ebola drug helped treat hospitalized Covid-19 patients, the common cold virus could become key in treating advanced unresectable cancers. 

Amazon’s Project Gesundheit, a multi-year project including more than 100 people, is focused on finding a cure for the common cold.

Vernalis plc announces today that the US Food and Drug Administration issued a Complete Response Letter (CRL) regarding the New Drug Application for CCP-07.